Stijn van Rompay
Gründer bei HYLORIS PHARMACEUTICALS SA
Vermögen: 96 Mio $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Thomas Jacobsen | M | 50 |
Hyloris Developments SA
 Hyloris Developments SA Pharmaceuticals: MajorHealth Technology Hyloris Developments SA is a Belgian pharmaceutical company that manufactures and sells pharmaceutical products. The private company is based in Liege, Belgium. The company was founded in 2013. The CEO is Stijn van Rompay. | 12 Jahre |
| Marie Gérard | F | - |
ImCyse SA
 ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 9 Jahre |
| Hugues Wallemacq | M | - |
EXO Biologics SA
 EXO Biologics SA BiotechnologyHealth Technology EXO Biologics SA operates as a Belgian biotechnology company. The company is based in Liege, Belgium. The company was founded in 2019. Hugues Wallemacq has been the CEO of the company since 2021.
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 4 Jahre |
| Carolyn Myers | M | 66 | 4 Jahre | |
| James Gale | M | 74 | 4 Jahre | |
| Dave Ahern | M | - |
Coalesce Product Development Ltd.
 Coalesce Product Development Ltd. Medical SpecialtiesHealth Technology Part of Novartis AG, Coalesce Product Development Ltd. is a British company that develops inhalation devices. The company is based in Cambridge, UK. The company was founded in 2009 by Dave Ahern, who has been the CEO since 2009. Coalesce Product Development was acquired by Sandoz AG on March 14, 2022. | - |
| Denis Bedoret | M | 43 |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 4 Jahre |
| Marc Foidart | M | - | 4 Jahre | |
| Sven Watthy | M | - | - | |
| Stefan Yee | M | 62 |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 5 Jahre |
| Chris Buyse | M | 59 | - | |
| Koenraad van der Elst | M | 63 | 4 Jahre | |
| Christina Franssen | M | - |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 5 Jahre |
| Vincent Brichard | M | - |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | - |
| Jean-Michel Foidart | M | 75 |
EXO Biologics SA
EXO Biologics SA BiotechnologyHealth Technology EXO Biologics SA operates as a Belgian biotechnology company. The company is based in Liege, Belgium. The company was founded in 2019. Hugues Wallemacq has been the CEO of the company since 2021. | 5 Jahre |
| Colin Clive Dalton | M | 74 |
Coalesce Product Development Ltd.
Coalesce Product Development Ltd. Medical SpecialtiesHealth Technology Part of Novartis AG, Coalesce Product Development Ltd. is a British company that develops inhalation devices. The company is based in Cambridge, UK. The company was founded in 2009 by Dave Ahern, who has been the CEO since 2009. Coalesce Product Development was acquired by Sandoz AG on March 14, 2022. | - |
| Thomas Taapken | M | 59 |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 5 Jahre |
| Dietmar Aichhorn | M | - | 4 Jahre | |
| Pieter van Rompay | M | - |
EXO Biologics SA
EXO Biologics SA BiotechnologyHealth Technology EXO Biologics SA operates as a Belgian biotechnology company. The company is based in Liege, Belgium. The company was founded in 2019. Hugues Wallemacq has been the CEO of the company since 2021. | 5 Jahre |
| Leon van Rompay | M | 75 | 4 Jahre | |
| Jean-Luc Vandebroek | M | 53 | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Pierre Vandepapeliere | M | - |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 4 Jahre |
| Marieke Vermeersch | F | - | - | |
| Jörg Neermann | M | 57 |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 2 Jahre |
| Edward J. Maloney | M | - | - | |
| Patrick Jeanmart | M | 51 | - | |
| Jean-Marie R. Saint-Remy | M | - |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 6 Jahre |
| Astrid Heiremans | F | - | - | |
| Maurizio Passanisi | M | - | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Belgien | 27 | 93,10% |
| Vereinigtes Königreich | 2 | 6,90% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Stijn van Rompay
- Persönliches Netzwerk
